DLBCL Debate: Bispecifics VS. CAR-T

DLBCL Debate: Bispecifics VS. CAR-T

DLBCL Debate: Bispecifics VS. CAR-T Welcome & introduction by host Maria Cristina Pirosa The case for CAR: why CAR T-cells can excel DLBCL care Federico Simonetta The case for Bispecifics: bispecific therapy can provide a dynamic approach to DLBCL management Thorsten...
Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia Welcome & introduction by host Davide Rossi Latest treatment strategies in frontline CLL George Follows Treatment sequencing in relapsed / recurrent CLL Nicole Lamanna Immunotherapies in CLL: CAR-T and bispecifics Davide Rossi  } 1 h 31...
Multiple Myeloma

Multiple Myeloma

Multiple Myeloma Welcome & introduction by host Mohamad Mohty What's new for induction in the transplant setting? Sonja Zweegman Current management of relapsed / recurrent myeloma Carmen de Ramon Ortiz Immunotherapies in myeloma: CAR-T and bispecifics Mohamad Mohty ...
Multiple Myeloma

Multiple Myeloma

Multiple Myeloma Welcome & introduction by host Mohamad Mohty Current SoC in 1L Multiple Myeloma (Transplant-Eligible and Non-Transplant-Eligible patients) Maria Victoria Mateos Multiple Myeloma Not Refractory to Lenalidomide Francesca Gay Multiple Myeloma Refractory...